EPISODE #158 Psychedelics: The Investment Case with Jaspreet Grewal, Mitchell Osak, & Steve Hajioff
This week, we’re joined by Jaspreet Grewal, Mitchell Osak, & Steve Hajioff - three subject matter specialists within the psychedelics space.
In this special panel episode, we explore the emergence (and re-emergence) of therapeutic psychedelics, including examining the substances which have gained early traction, the investment case for them, and the challenges and opportunities of this new sector.
📚 VIEW SHOW NOTES AND EXTRAS:
[Psilocybin] can't be viewed as a miracle drug for everybody. I think that's really what it comes down to. We have to be very pragmatic that it's still an investigational compound. - Jaspreet
Connect with Steve on Linkedin: https://www.linkedin.com/in/stevehajioff/?originalSubdomain=uk
Connect with Jaspreet on Linkedin: https://www.linkedin.com/in/jkgrewal/
Connect with Mitchell on Linkedin: https://www.linkedin.com/in/mitchellosak/